Company Introduction

Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China and Boston, USA.

Our current therapeutic areas of interest include oncology, metabolic diseases and autoimmune diseases. By leveraging our industry-leading core strength in CARD (Computer Accelerated Rational Discovery), Regor is committed to creating a highly efficient ecosystem for accelerated discovery of innovative therapeutic agents with differentiated therapeutic values for patients around the world. With a strong focus on excellence in pharmaceutical research and global competitiveness, we aspire to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.

Mission and Strategy

To serve patients around the world through innovative and clinically differentiated drugs
Accelerated
Discovery
Breakthrough
Medicines
To accelerate portfolio delivery and value creation through enabling technology platforms

Leadership Team

Regor Founders

  • Xiayang Qiu
    PhD

    Chief Executive Officer

  • Min Zhong
    PhD, MBA

    Chief Operating Officer

  • Xiaotian Zhu
    PhD

    President of US Operations

  • Wenge Zhong
    PhD

    Chief Technology Officer

Leadership Team

  • David J. Valacer
    MD, MS

    Chief Medical Officer

  • Jing Lin
    PhD

    Vice President, Preclinical Research and Clinical Pharmacology

  • Julie Xie
    PhD

    Vice President, Biology

  • Xi Chen
    MBA

    Vice President, Business Operation

  • Jincao Zheng
    MD

    CMO-China

  • Mark Pirner
    MD PhD

    Vice President, Endocrinology and Metabolism

  • Jinyang Hong
    PhD

    Senior Vice President-Pharmaceutical Science(CMC)

Scientific Advisory Board

  • Rikard Holmdahl
    MD/PhD

    Professor of Medical Inflammation Research, Karolinska Institute

  • Janet Hammond
    MD

    Vice President and Therapeutic Area Head at AbbVie

Value and Culture

S cience Based

T eam Spirit

A ccountability and Integrity

R esults and Quality

S hared Dream,Passion and Success

Aspiration

Be STARS of HOPE for Patients

Therapeutic Areas

We have embarked upon three therapeutic areas, Metabolic diseases, Oncology, and Immunology.

Oncology

Our research and development efforts aim to generate effective therapeutics solutions based on our profound understanding to molecular targets and pathways in immune-oncology and tumor proliferation add development. We seek deep insights on which tumor pathogenesis, development and interaction with immune system is based, and thus innovate pan-tumor treatment modality with FIC/BIC new molecular entities to bring new hope to patients worldwide.

Metabolic Disorders

Metabolic disorders including diabetes, obesity and NASH caused significant healthcare burden globally and deeply impact way of lives of hundreds of millions of world population. Our drug discovery and development in this therapeutic area envisions a novel solution with effective metabolic profile management that significantly improves patients’ quality of life and provide patients with better experience of drug administration so that an effective long-term disease management can be realized.

Immunology

Auto-immune disease patients suffers from disease attack and progress with a long course of journey and thus quality of life is severely impacted. Patients are faced with tremendous unmet medical needs with current disease modifying medications. Our research and development platform is developing next generation anti-autoimmune medication that seek breakthrough in mode of actions and fulfill more effective disease management and control.

245 Main Street, Second Floor, Cambridge, MA 02142, USA
1206 Zhangjiang Rd, Building C, Pudong New District, Shanghai 201210, China